Literature DB >> 3677282

The effect of procainamide on plasma cholinesterase activity.

J R Kambam1, R J Naukam, B V Sastry.   

Abstract

The in vitro effect of procainamide on plasma cholinesterase (PCHE) activity in the plasma of ten normal ASA physical status I patients was studied using a kinetic method. The mean plasma cholinesterase activity without procainamide (control) was 0.90 +/- 0.09 units.ml-1. The dibucaine numbers of all the samples were in the normal range of 78 to 86, indicating normal genotypes. The mean plasma cholinesterase activity, in the presence of procainamide in concentrations of 5.0, 10.0, 20.0 and 40.0 micrograms.ml-1, was reduced to 0.73 +/- 0.04, 0.61 +/- 0.03, 0.45 +/- 0.02, and 0.36 +/- 0.01 units.ml-1, respectively. At therapeutic concentrations of 4 to 12 micrograms.ml-1, procainamide inhibited cholinesterase activity 15 to 30 per cent. The authors also showed that the concentration of procainamide required to inhibit 50 per cent of plasma cholinesterase activity was 20 micrograms.ml-1 (I50). The authors conclude that procainamide when tested in vitro had a statistically significant depressant effect on plasma cholinesterase activity at all the concentrations studied.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3677282     DOI: 10.1007/bf03010515

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  11 in total

1.  SERUM CHLONESTERASE ACTIVITY DURING PREGNANCY, LABOR AND THE PUERPERIUM.

Authors:  S M SHNIDER
Journal:  Anesthesiology       Date:  1965 May-Jun       Impact factor: 7.892

2.  The relation between plasma cholinesterase and prolonged apnea caused by succinylcholine.

Authors:  F F FOLDES; V M FOLDES; J C SMITH; E K ZSIGMOND
Journal:  Anesthesiology       Date:  1963 Mar-Apr       Impact factor: 7.892

3.  Hexafluorenium: its anticholinesterase and neuromuscular activity.

Authors:  F F FOLDES; R E MOLLOY; E K ZSIGMOND; J A ZWARTZ
Journal:  J Pharmacol Exp Ther       Date:  1960-08       Impact factor: 4.030

4.  Substrate competition procaine and succinylcholine diiodide for plasma cholinesterase.

Authors:  F F FOLDES; P G MCNALL; C H ELLIS; D L DAVIS; A L WNUCK
Journal:  Science       Date:  1953-04-10       Impact factor: 47.728

5.  Potentiation of succinylcholine by procaine.

Authors:  A S SALGADO
Journal:  Anesthesiology       Date:  1961 Nov-Dec       Impact factor: 7.892

6.  Serum cholinesterase activity in the normal individual and in people with liver disease.

Authors:  K KAUFMAN
Journal:  Ann Intern Med       Date:  1954-09       Impact factor: 25.391

7.  Human ventricular refractoriness. II. Effects of procainamide.

Authors:  J A Kastor; M E Josephson; S B Guss; L N Horowitz
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

8.  A kinetic method for the estimation of pseudocholine esterase using naphthyl acetate substrate.

Authors:  P W Zapf; C M Coghlan
Journal:  Clin Chim Acta       Date:  1973-03-14       Impact factor: 3.786

9.  The effect of quinidine and procainamide on the neuromuscular blocking action of suxamethonium.

Authors:  M F Cuthbert
Journal:  Br J Anaesth       Date:  1966-10       Impact factor: 9.166

10.  The use of echothiophate in myasthenia gravis.

Authors:  F F Foldes; V M Foldes; P G McNall
Journal:  Clin Pharmacol Ther       Date:  1966 Sep-Oct       Impact factor: 6.875

View more
  4 in total

1.  Metoclopramide inhibits plasma cholinesterase.

Authors:  S G Graham; A M Burgess
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

2.  The inhibitory effect of metoclopramide on plasma cholinesterase activity.

Authors:  J R Kambam; W C Parris; J J Franks; B V Sastry; R Naukam; B E Smith
Journal:  Can J Anaesth       Date:  1988-09       Impact factor: 5.063

3.  The characteristics of the inhibition of serum cholinesterase by metoclopramide.

Authors:  S G Graham; A W Crossley
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.